Will Ideaya Biosciences stock go up?

According to Danelfin AI, Ideaya Biosciences has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (56.59%) is +5.77% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Ideaya Biosciences stock?

The Ideaya Biosciences target price is $52 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Ideaya Biosciences stock right now?

Ideaya Biosciences has today a Hold rating (AI Score 6/10), according to Danelfin AI. Its probability of beating the market in 3 months (56.59%) is +5.77% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Ideaya Biosciences stock is a good buy .

Is Ideaya Biosciences undervalued right now?

Based on analysts, the average price target upside for Ideaya Biosciences is +43.69% (1Y). According to Danelfin AI, Ideaya Biosciences has today an AI Score of 6/10 (Hold Rating).

What was the price range of Ideaya Biosciences stock over the past 12 months?

The Ideaya Biosciences stock price range over the past 12 months has been $21.02 - $37.86.

What is going on with Ideaya Biosciences stock in the last 3 months?

The Ideaya Biosciences stock performance in the last quarter has been +8.61%.

Does Ideaya Biosciences offer dividend payments?

No, Ideaya Biosciences does not currently pay dividends.

What is the current market capitalization of Ideaya Biosciences?

Ideaya Biosciences's market cap is $3.44B, as of 2026-07-02 08:00.

When is the next IDYA earnings report date?

IDYA will publish its next earnings report on 2026-05-05.

IDEAYA Biosciences Inc (IDYA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

IDYA AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, IDEAYA Biosciences Inc today receives an AI Score of 6/10, which translates to a Hold rating. The stock has a 57% probability of outperforming the market in the next 3 months, which is 6% higher than the average probability of any stock (51%). The top positive contributors include the long tail of fundamentals impact (+3.58%), operating cash flow (bottom 10%) (+1.27%), chart pattern (252d) (+1.01%), the Biotechnology industry (+0.95%), and the long tail of technicals (+0.94%). On the detractor side, the chart pattern (504d) (-1.51%), Fear & Greed Index (value 31) (-0.81%), analyst lowest price upside (top 50%) (-0.50%), chart pattern (120d) (-0.43%), distance from KAMA (20d) (top 10%) (-0.38%), and ATR (14d volatility) (top 30%) (-0.34%) weigh down the probability. Notable data points include a cash per share of $7.06 (top 20%), tangible shareholders' equity of $937.27M (top 30%), and an EPS estimate for next quarter of -$1.06 (bottom 10%). The stock also has a negative operating cash flow (-$75.17M, bottom 10%) and an earnings countdown of -52 days (bottom 20%), indicating the last earnings report was over a month ago. The Fear & Greed Index at 31 suggests fear in the market, which historically can be a contrarian positive signal but here detracts. Overall, the stock's probability is boosted by fundamentals and industry tailwinds but tempered by technical patterns and volatility, resulting in a balanced HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+4.27%
How the stock is priced relative to its fundamentals
Earnings Quality+1.47%
Stability and reliability of reported earnings
Sentiment+0.46%
How analysts and the market view the stock
Growth+0.43%
Expected pace of revenue and earnings expansion
Size & Liquidity+0.24%
Company size and trading liquidity

Profitability-0.61%
Profitability and operating efficiency metrics
Volatility-0.34%
How much the stock price tends to fluctuate
Momentum-0.15%
Direction and strength of recent price movements

IDYA probability advantage of beating the market (3M):

+5.77%

Technical

Ideaya Biosciences (IDYA) has a Technical Score of 5/10 because, according to only technical analysis, it has a probability advantage of -1.98% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.64%) and the probability of IDYA (48.66%) of overperforming the market in the next 3 months, as determined by Danelfin AI’s technical analysis.

Average probability of any US-listed stock of beating the market (3M)50.64%
IDYA probability advantage of beating the market (only technical, 3M)-1.98%
IDYA probability of beating the market (3M)48.66%

IDYA probability advantage of beating the market (only technical, 3M): -1.98%

The AI-powered technical analysis of Ideaya Biosciences (IDYA) is only based on the 29 technical features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of IDYA:

Type	Alpha Signal	Probability Advantage Impact (3M)
Technical	Upgrade to Pro to unlock	-223.07%
Technical	Upgrade to Pro to unlock	+92.86%
Technical	Upgrade to Pro to unlock	+73.09%
Technical	Upgrade to Pro to unlock	+61.42%
Technical	Upgrade to Pro to unlock	+53.39%
Technical	Upgrade to Pro to unlock	-50.59%
Technical	Upgrade to Pro to unlock	-50.55%
Technical	Upgrade to Pro to unlock	+48.71%
Technical	Upgrade to Pro to unlock	-48.52%
Technical	Upgrade to Pro to unlock	-40.94%
Technical	Upgrade to Pro to unlock	+35.86%
Technical	Upgrade to Pro to unlock	+34.77%
Technical	Upgrade to Pro to unlock	+32.63%
Technical	Upgrade to Pro to unlock	-27.67%
Technical	Upgrade to Pro to unlock	-27.01%

Rest of Alpha Signals: +127.66%

IDYA probability advantage of beating the market (only technical, 3M)Total:-1.98%
IDYA Technical Score

Significant changes Vs previous day

IDYA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$36.19
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

IDYA Proven Hold Signal & Price Forecast

This is the price chart for IDYA from January 2, 2026 until today. The chart indicates, in yellow, the 63 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

IDYA Average Past Performance & Win Rate

Three months after its 1000 Hold signals since July 2026, IDYA had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

1000 Past IDYA Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+45.70%
Average Alpha				+31.79%
Win Rate (% Positive Perf.)				59.42%
% Positive Alpha				53.60%

IDYA Frequently Asked Questions

Will Ideaya Biosciences stock go up?
According to Danelfin AI, Ideaya Biosciences has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (56.59%) is +5.77% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Ideaya Biosciences stock?
Is it a good time to buy, sell, or hold Ideaya Biosciences stock right now?
Is Ideaya Biosciences undervalued right now?
What was the price range of Ideaya Biosciences stock over the past 12 months?
What is going on with Ideaya Biosciences stock in the last 3 months?
Does Ideaya Biosciences offer dividend payments?
What is the current market capitalization of Ideaya Biosciences?
When is the next IDYA earnings report date?

IDEAYA Biosciences Inc Company Profile

IDEAYA Biosciences, Inc. is a precision medicine oncology firm centered on synthetic lethality. It is committed to discovering and developing targeted therapeutics for select patient demographics determined via molecular diagnostics across the United States. The company's innovation pipeline comprises several audacious products at different stages of development. Notably, IDE196 is making strides in Phase 2/3 clinical trials as a protein kinase C sentinel, focusing on genetically specific cancers identified by GNAQ or GNA11 gene mutations.

Furthermore, IDE397, a methionine adenosyltransferase 2a inhibitor and trailblazer in its field, currently explores Phase 1/2 trials to slug it out with solid tumors sparked by methylthioadenosine phosphorylase gene deletions — typically found lurking within non-small cell lung, bladder, gastric, and esophageal cancers.

Simultaneously, two other candidates named IDE161 and GSK101 are edging their way forward through Phase 1 trials as deterrents against tumors with variations in homologous recombination deficiency (HRD) or BRCA genes respectively. What's more? A family of Werner Helicase inhibitors lay siege on tumors embedded with high microsatellite instability too.

Taking it beyond clinical applications, IDEAYA Biosciences leads several exploratory endeavors focused around pharmacological inhibition; DECIPHER dual CRISPR library points toward fresh opportunities in synthetic lethality target and biomarker discovery while INQUIRE chemical library partnered with HARMONY machine-learning engines targets scaling up its drug discovery platform.

The company owes part of its profundity to strategic alliances forged with renowned entities such as GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester.

Originally incorporated in 2015 under California skies at South San Francisco's bustling biotech hub, IDEAYA Biosciences stands today as a stalwart in its commitment to patient-centric, precision oncology research and development.

Sector:Health Care
Country:United States
Industry:
Address:7000 Shoreline Ct, Suite 350, South San Francisco
Employees:145
Website:ideayabio.com

Pros

Pricing power for novel oncology therapies

Intellectual property protection via drug patents

Regulatory barriers to market entry

Potential for broad indication expansion post-approval

Switching costs for established effective treatments

Cons

Capital intensity for drug development

IDYA Stock AI Analysis